Colistin plus meropenem for carbapenem-resistant Gram-negative infections: In vitro synergism is not associated with better clinical outcomes A Nutman, J Lellouche, E Temkin, G Daikos, A Skiada, ... Clinical Microbiology and Infection 26 (9), 1185-1191, 2020 | 64 | 2020 |
Simulation-based evaluation of PK/PD indices for meropenem across patient groups and experimental designs AN Kristoffersson, P David-Pierson, NJ Parrott, O Kuhlmann, T Lave, ... Pharmaceutical research 33, 1115-1125, 2016 | 64 | 2016 |
Semi-mechanistic pharmacokinetic–pharmacodynamic modelling of antibiotic drug combinations MJE Brill, AN Kristoffersson, C Zhao, EI Nielsen, LE Friberg Clinical Microbiology and Infection 24 (7), 697-706, 2018 | 55 | 2018 |
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant … Y Dickstein, L Leibovici, D Yahav, N Eliakim-Raz, GL Daikos, A Skiada, ... BMJ open 6 (4), e009956, 2016 | 51 | 2016 |
Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model AF Mohamed, AN Kristoffersson, M Karvanen, EI Nielsen, O Cars, ... Journal of Antimicrobial Chemotherapy 71 (5), 1279-1290, 2016 | 48 | 2016 |
Population pharmacokinetics of piperacillin in sepsis patients: should alternative dosing strategies be considered? MG Andersen, A Thorsted, M Storgaard, AN Kristoffersson, LE Friberg, ... Antimicrobial agents and chemotherapy 62 (5), 10.1128/aac. 02306-17, 2018 | 44 | 2018 |
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria AN Kristoffersson, V Rognås, MJE Brill, Y Dishon-Benattar, ... Clinical Microbiology and Infection 26 (12), 1644-1650, 2020 | 27 | 2020 |
Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy? SF Maarbjerg, A Thorsted, A Kristoffersson, LE Friberg, EI Nielsen, ... Pediatric blood & cancer 66 (6), e27654, 2019 | 18 | 2019 |
A novel mechanism-based pharmacokinetic–pharmacodynamic (PKPD) model describing ceftazidime/avibactam efficacy against β-lactamase-producing Gram-negative bacteria AN Kristoffersson, C Bissantz, R Okujava, A Haldimann, I Walter, T Shi, ... Journal of Antimicrobial Chemotherapy 75 (2), 400-408, 2020 | 16 | 2020 |
Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen A Thorsted, AN Kristoffersson, SF Maarbjerg, H Schrøder, M Wang, ... Journal of Antimicrobial Chemotherapy 74 (10), 2984-2993, 2019 | 12 | 2019 |
Inter occasion variability in individual optimal design AN Kristoffersson, LE Friberg, J Nyberg Journal of Pharmacokinetics and Pharmacodynamics 42, 735-750, 2015 | 10 | 2015 |
Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli DD Khan, P Lagerbäck, C Malmberg, AN Kristoffersson, E Wistrand-Yuen, ... International journal of antimicrobial agents 51 (3), 399-406, 2018 | 6 | 2018 |
Study Design and Dose Regimen Evaluation of Antibiotics based on Pharmacokinetic and Pharmacodynamic Modelling A Kristoffersson Acta Universitatis Upsaliensis, 2015 | 5 | 2015 |
Bounded integer model‐based analysis of psoriasis area and severity index in patients with moderate‐to‐severe plaque psoriasis receiving BI 730357 QX Ooi, A Kristoffersson, J Korell, M Flack, E L. Plan, B Weber CPT: Pharmacometrics & Systems Pharmacology, 2023 | 4 | 2023 |
Optimal design (OD) and in vitro validation of reduced time–kill curve experiments for pharmacokinetic-pharmacodynamic (PK/PD) modeling AN Kristoffersson, LE Friberg Fifty-fourth Interscience Conference on Antimicrobial Agents and …, 2014 | 2 | 2014 |
Optimal design of in vitro time kill curve experiments for the evaluation of antibiotic effects A Kristoffersson, AC Hooker, MO Karlsson, LE Friberg 20th Population Approach Group Europe (PAGE) Meeting, 0 | 1 | |
Quantifying combined effects of colistin and ciprofloxacin against Escherichia coli in an in silico pharmacokinetic-pharmacodynamic model C Zhao, AN Kristoffersson, DD Khan, P Lagerbäck, U Lustig, S Cao, ... | | 2023 |
Erratum to: Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen A Thorsted, AN Kristoffersson, SF Maarbjerg, H Schrøder, M Wang, ... Journal of Antimicrobial Chemotherapy 75 (1), 254-255, 2020 | | 2020 |
Suboptimal Piperacillin-Exposure Following Bolus Administration in Children with Chemotherapy-Induced Fever SF Maarbjerg, AN Kristoffersson, LE Friberg, B Brock, H Schroder Pediatric Blood and Cancer 65 (2), S524, 2018 | | 2018 |
Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant … Y Dickstein, L Leibovici, D Yahav, N Eliakim-Raz, GL Daikos, A Skiada, ... | | 2016 |